Medincell Stock Rebounds by 2.5% and Moves Above Its Moving Averages
The biotech company from Montpellier moves forward in early afternoon, going against a downward trending Parisian market. The stock ranks among the top gainers in the SBF 120, continuing the rebound that began after the fall following the annual accounts published in mid-June.
Medincell Moves Above Its Three Key Moving Averages
Medincell stock gains 2.5% to €26.63 during the session, up from a last close at €25.98. This marks a weekly gain of 10.6%, partially offsetting a monthly decline of 6.4%. Over a year, the performance is nearly 59%.
Today's movement repositions the stock above its three main moving averages, with a gap of 0.68% over the MM20 (€26.45), 1.91% over the MM50 (€26.13), and 1.87% over the MM200 (€26.14). This reconvergence of the three curves around the price indicates stabilization after the post-publication turbulence. The RSI at 49 remains neutral, with no extreme signals, and the price is now midway between the support at €24.08 and the resistance at €28.52.
Shift Towards Recurring Revenues Sets the Direction After the June 16 Publication
The session extends the recovery that began on June 18, the day after the penalty imposed following the annual accounts publication. In the 2025/2026 fiscal year (published on June 16), royalties from Uzedy jumped by 42% to €9.3 million, while the net loss widened to €31.3 million due to accelerated R&D investments and the absence of exceptional revenues. The company identified, during the same publication, the commercial launch of olanzapine LAI scheduled for Q4 2026, alongside the continued increase in Uzedy royalties.
The expected rise in operating expenses remains cited among the risks. In the short term, a clear crossing of the €28.52 resistance will be the next technical threshold to watch to validate the exit from the consolidation zone opened in mid-June.
